Quercegen Technologies

Quercegen Technologies is a clinical-stage biotechnology company specializing in the development of flavonoid-based therapeutics with enhanced bioavailability. The company's primary focus is on isoquercetin, a small molecule inhibitor of protein disulfide isomerase (PDI), which plays a critical role in thrombus formation and inflammation. Quercegen's lead programs target the prevention of cancer-associated thrombosis and the treatment of complications related to COVID-19 and chronic kidney disease. By utilizing proprietary enzymatic processes, the company aims to transform naturally occurring compounds into potent, pharmaceutical-grade treatments. Their clinical development is supported by collaborations with leading academic medical centers in the United States.